Search results
Showing 7981 to 7995 of 8980 results
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
In development Reference number: GID-MT594 Expected publication date: TBC
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued Reference number: GID-TA11261
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)
This guidance has been updated and replaced by NICE HealthTech guidance 668.
Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]
Discontinued Reference number: GID-TA10443
Discontinued Reference number: GID-TA10445
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
In development Reference number: GID-TA11070 Expected publication date: TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC
Discontinued Reference number: GID-SGWAVE0761
In development Reference number: GID-TA11301 Expected publication date: TBC